马立巴韦对比缬更昔洛韦治疗移植后CMV感染的AURORA试验中国亚组分析
该研究为Ⅲ期多中心随机双盲阳性对照试验的中国亚组分析,纳入18例造血干细胞移植后无症状CMV感染患者,马立巴韦组与缬更昔洛韦组各9例。第8周两组确认CMV病毒血症清除率均为77.8%,未校正差异0.0%(95%CI -38.4%~38.4%)。马立巴韦组中性粒细胞减少症发生率数值上低于缬更昔洛韦组(22.2%对55.6%)。
要点
- 中国亚组中马立巴韦与缬更昔洛韦第8周CMV清除率相同,均为77.8%。
- 马立巴韦组治疗相关严重不良事件发生率为0,缬更昔洛韦组为22.2%。
- 马立巴韦组中性粒细胞减少症发生率22.2%,低于缬更昔洛韦组的55.6%。
核心结论
- 在中国人群中,马立巴韦治疗HSCT受者无症状CMV感染的病毒血症清除效果与缬更昔洛韦相当,安全性可接受且耐受性良好。
- 马立巴韦组中性粒细胞减少症发生率在数值上低于缬更昔洛韦组。
研究设计与样本
- Ⅲ期、多中心、随机、双盲、阳性对照研究(AURORA试验中国亚组分析)。
- 中国亚组共纳入18例HSCT后首次无症状CMV感染患者,马立巴韦组与缬更昔洛韦组各9例,按1∶1随机分配。
- 马立巴韦400 mg每日2次,缬更昔洛韦剂量根据肌酐清除率调整,治疗8周,随访至第20周。
主要发现
- 第8周确认CMV病毒血症清除率两组均为77.8%,未校正差异0.0%(95%CI -38.4%~38.4%)。
- 第8周清除并维持至第16周的应答者比例马立巴韦组44.4%,缬更昔洛韦组55.6%,未校正差异-11.1%(95%CI -57.0%~34.8%)。
- 治疗观察期间至少发生1起TEAE的比例两组均为100%,因TEAE停用研究药物的比例分别为11.1%和33.3%。
- 治疗相关SAE发生率马立巴韦组为0,缬更昔洛韦组为22.2%。
- 中性粒细胞减少症发生率马立巴韦组22.2%,缬更昔洛韦组55.6%。
临床怎么用
- 对于HSCT后无症状CMV感染的中国患者,马立巴韦可作为缬更昔洛韦的替代选择之一,尤其需关注中性粒细胞减少风险时。
- 治疗期间应监测CMV病毒血症清除情况及不良事件,马立巴韦组TEAE发生率亦为100%。
局限性
- 中国亚组样本量仅18例,置信区间较宽,结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: This study aimed to compare the efficacy and safety of maribavir and valganciclovir in the treatment of asymptomatic cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) recipients. Methods: In this phase 3, multicenter, randomized, double-blind, positive-controlled study, subjects with first episode of asymptomatic CMV infection post-HSCT were randomly assigned in a 1∶1 ratio to receive maribavir (400 mg, twice daily) or valganciclovir (dose-adjusted for renal clearance) for 8 weeks with a follow-up period spanned from 8 to week 20. The primary efficacy endpoint includes confirmed CMV viremia clearance at 8 weeks. Safety assessment included treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) . Results: The Chinese population subgroup included 18 subjects, comprising 9 subjects each in the maribavir and valganciclovir arms. At 8 weeks, 77.8% of the subjects in both arms achieved confirmed CMV viremia clearance, with an unadjusted difference (maribavir vs valganciclovir) of 0.0% (95% CI: -38.4% to 38.4% ). The proportions of responders who achieved CMV viremia clearance at 8 weeks and maintained it until 16 weeks were 44.4% and 55.6% in the maribavir and valganciclovir arms, respectively, with an unadjusted difference of -11.1% (95% CI: -57.0% to 34.8% ). During the treatment observation period, 100% of subjects in both the maribavir and valganciclovir arms experienced at least one TEAE, causing 11.1% and 33.3% of subjects, respectively, to discontinue the study drug. The incidence of treatment-related SAEs was 0 and 22.2% in the maribavir and valganciclovir arms, respectively. Further, the incidence of neutropenia during the treatment observation period was lower in the maribavir arm than in the valganciclovir arm (22.2% vs 55.6% ) . Conclusion: In the Chinese population, maribavir may be comparable to valganciclovir in clearing CMV viremia to treat HSCT recipients with asymptomatic CMV infection, with acceptable safety and good tolerability, especially being numerically lower than valganciclovir in terms of neutropenia. 目的: 比较马立巴韦与缬更昔洛韦在造血干细胞移植(HSCT)受者中治疗无症状巨细胞病毒(CMV)感染的疗效和安全性。 方法: 这项Ⅲ期、多中心、随机、双盲、阳性对照研究将HSCT后首次发生的无症状CMV感染的参与者按1∶1的比例随机接受马立巴韦(400 mg,每日2次)或缬更昔洛韦(450 mg,每日1次至900 mg每日2次,剂量基于肌酐清除率调整)治疗8周,随访时间为研究第8~20周。主要疗效终点是在研究第8周结束时确认的CMV病毒血症清除。安全性评价包括治疗期间出现的不良事件(TEAE)和严重不良事件(SAE)。 结果: 共随机入组18例来自中国亚组人群的参与者,马立巴韦组和缬更昔洛韦组各9例参与者。在第8周时,马立巴韦组和缬更昔洛韦组均有77.8%的参与者达到了确认的CMV病毒血症清除,未校正差异(马立巴韦对缬更昔洛韦)为0.0%(95% CI: -38.4%, 38.4%)。马立巴韦组和缬更昔洛韦组在第8周达到CMV血症清除并维持至第16周的应答者比例分别为44.4%和55.6%,未校正差异为-11.1%(95% CI: -57.0%, 34.8%)。马立巴韦组和缬更昔洛韦组治疗观察期间至少发生1起TEAE的参与者比例均为100%,因TEAE导致停用研究药物的参与者比例分别为11.1%和33.3%,治疗相关SAE发生率分别为0和22.2%。马立巴韦组在治疗观察期间中性粒细胞减少症发生率在数值上低于缬更昔洛韦组(22.2%对55.6%)。 结论: 在中国人群中,马立巴韦治疗无症状CMV感染的HSCT受者中清除CMV病毒血症方面与缬更昔洛韦相当,且具有可接受的安全性和良好的耐受性,特别是中性粒细胞减少症的发生率低于缬更昔洛韦组。.
引用
- Xuan L, Huang H, Xu LP, et al. [Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on the efficacy and safety of maribavir compared with valganciclovir in the treatment of post-transplant cytomegalovirus infection: Subgroup analysis of AURORA Trial in the Chinese population]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41486656. doi:10.3760/cma.j.cn121090-20250626-00300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。